Computational Analysis for Prediction of Multi Epitopes Vaccine against Blue Tongue Virus Serotype 4 from VP5 and VP7 Proteins

{"title":"Computational Analysis for Prediction of Multi Epitopes Vaccine against Blue\nTongue Virus Serotype 4 from VP5 and VP7 Proteins","authors":"","doi":"10.33140/jcei.05.02.03","DOIUrl":null,"url":null,"abstract":"Blue Tongue Disease (BTD) is a non-contagious insect transmitted disease of ruminants caused by double stranded RNA virus.\nThis study aimed to predict an effective multi-epitopes vaccine against BTD from VP5 and VP7 as immunogenic proteins using\nimmunoinformatic tools. The VP5 and VP7 proteins sequences were retrieved from GenBank of National Center for Biotechnology\nInformation (NCBI). The sequences of each protein were aligned for conservancy using Bioedit software. Immune Epitope\nDatabase (IEDB) analysis resources were used to predict B and T cell epitopes. The proposed MHC-1 epitopes of both proteins\nwere further subjected to molecular docking to show minimum binding energy of each epitopes. In our results, two epitopes\n(235-SEEV-235 and 85-PDPLSP-90) from VP5 and two epitopes (79-PISPDYTQ-86 and 297-PIFPPN-302) from VP7 were\nproposed as B cell epitopes since they were shown to be linear, surface accessible and antigenic epitopes. For T cells, MHC-1\nbinding prediction tools showed multiple epitopes strongly interacted with BoLA alleles from both VP5 and VP7. Among them\nthree epitopes, (257-KLKKVINAL-265, 487-QMHILRGPL-495 and 350-VMMRFKIPR-358) fromVP5 protein and four epitopes\n(86-QHMATIGVL-94, 315-TLADVYTVL-323, 17-TLQEARIVL-25 and 10-TVMRACATL-18) from VP7 protein interacted\nwith the highest number of alleles and demonstrated best binding affinity to MHC-1 alleles. Thus were proposed as a vaccine\ncandidate from VP5 and VP7 proteins. All the epitopes from VP5 and VP7 that interacted with MHC-1 alleles when subjected\nto molecular docking against the sheep b_microglobulin alleles demonstrated biologically significant higher binding affinity\nwhich expressed by their lower global and attractive energy. In conclusion, eleven epitopes were predicted as promising vaccine\ncandidates against BTD from the VP5 and VP7 immunogenic proteins. These epitopes require to be validated experimentally\nthrough in vitro and in vivo studies.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"32 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical & experimental immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/jcei.05.02.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Blue Tongue Disease (BTD) is a non-contagious insect transmitted disease of ruminants caused by double stranded RNA virus. This study aimed to predict an effective multi-epitopes vaccine against BTD from VP5 and VP7 as immunogenic proteins using immunoinformatic tools. The VP5 and VP7 proteins sequences were retrieved from GenBank of National Center for Biotechnology Information (NCBI). The sequences of each protein were aligned for conservancy using Bioedit software. Immune Epitope Database (IEDB) analysis resources were used to predict B and T cell epitopes. The proposed MHC-1 epitopes of both proteins were further subjected to molecular docking to show minimum binding energy of each epitopes. In our results, two epitopes (235-SEEV-235 and 85-PDPLSP-90) from VP5 and two epitopes (79-PISPDYTQ-86 and 297-PIFPPN-302) from VP7 were proposed as B cell epitopes since they were shown to be linear, surface accessible and antigenic epitopes. For T cells, MHC-1 binding prediction tools showed multiple epitopes strongly interacted with BoLA alleles from both VP5 and VP7. Among them three epitopes, (257-KLKKVINAL-265, 487-QMHILRGPL-495 and 350-VMMRFKIPR-358) fromVP5 protein and four epitopes (86-QHMATIGVL-94, 315-TLADVYTVL-323, 17-TLQEARIVL-25 and 10-TVMRACATL-18) from VP7 protein interacted with the highest number of alleles and demonstrated best binding affinity to MHC-1 alleles. Thus were proposed as a vaccine candidate from VP5 and VP7 proteins. All the epitopes from VP5 and VP7 that interacted with MHC-1 alleles when subjected to molecular docking against the sheep b_microglobulin alleles demonstrated biologically significant higher binding affinity which expressed by their lower global and attractive energy. In conclusion, eleven epitopes were predicted as promising vaccine candidates against BTD from the VP5 and VP7 immunogenic proteins. These epitopes require to be validated experimentally through in vitro and in vivo studies.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用VP5和VP7蛋白预测蓝舌病毒4型多表位疫苗的计算分析
蓝舌病是由双链RNA病毒引起的反刍动物非传染性虫传疾病。本研究旨在利用免疫信息学工具,从VP5和VP7作为免疫原性蛋白,预测一种有效的BTD多表位疫苗。VP5和VP7蛋白序列从美国国家生物技术信息中心(NCBI)基因库检索。利用Bioedit软件对各蛋白序列进行比对。免疫表位数据库(IEDB)分析资源用于预测B和T细胞表位。两种蛋白的MHC-1表位进一步进行分子对接,以显示每个表位的结合能最小。在我们的研究结果中,来自VP5的两个表位(235-SEEV-235和85-PDPLSP-90)和来自VP7的两个表位(79-PISPDYTQ-86和297-PIFPPN-302)被认为是B细胞表位,因为它们被证明是线性的,表面可接近的和抗原性的表位。对于T细胞,mhc -1结合预测工具显示多个表位与VP5和VP7的BoLA等位基因强烈相互作用。其中vp5蛋白的3个表位(257-KLKKVINAL-265、487-QMHILRGPL-495和350-VMMRFKIPR-358)和VP7蛋白的4个表位(86- qhmatigv1 -94、315- tladvytv1 -323、17-TLQEARIVL-25和10-TVMRACATL-18)与MHC-1等位基因的相互作用数量最多,与MHC-1等位基因的结合亲和力最好。因此,从VP5和VP7蛋白中提出了一种候选疫苗。VP5和VP7的表位在与绵羊微球蛋白等位基因进行分子对接时,与MHC-1等位基因相互作用的表位均表现出生物学上显著的高结合亲和力,这表现为它们较低的全局能和吸引能。总之,从VP5和VP7免疫原性蛋白中预测了11个表位作为抗BTD的有希望的候选疫苗。这些表位需要通过体外和体内研究进行实验验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Other Sea Star Igkappa Gene Cloning Assay in E.Coli with New Parameters Australian COVID-19 pandemic: A Bradford Hill Analysis of Iatrogenic Excess Mortality Nutritional Management of Celiac Disease Cinnamein Inhibits the Induction of Nitric Oxide and Proinflammatory Cytokines in Macrophages, Microglia and Astrocytes. Therapeutic Monoclonal Antibodies Approved by FDA in 2022
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1